



Claims

1. A depsipeptide compound represented by the formula (I) or (II), or a pharmaceutically acceptable salt thereof.



2. An isomer of a depsipeptide compound having the planar structural formula represented by the formula (I) described in claim 1 and an optical rotation $[\alpha]^{25}_D$ of -349.3 degree (c 0.05, methanol solvent), an isomer of a depsipeptide compound having the planar structural formula represented by the formula (II) described in claim 1 and an optical rotation $[\alpha]^{25}_D$ of -65.3 degree (c 0.20, methanol solvent), or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising the depsipeptide compound or the pharmaceutically acceptable

salt thereof according to claim 1 and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition according to claim 3, which is an antitumor agent.

5. Use of the depsipeptide compound or the pharmaceutically acceptable salt thereof according to claim 1 for the production of a medicament which is an antitumor agent.

6. A method which is a method for treating a patient suffering from cancer and comprises administering an effective amount of the depsipeptide compound or the pharmaceutically acceptable salt thereof according to claim 1 to the patient.